Send to printer »

GEN News Highlights : Jul 10, 2007

OncoMethylome Enhances Pharmacogenomic Services in Deal with BioTrove

OpenArray nanoplates and instrumentation will be utilized in R&D of DNA methylation-based cancer biomarkers.

OncoMethylome Sciences will use BioTrove's OpenArray™ PCR screening technology in the development of DNA gene methylation cancer biomarkers.

OncoMethylome products are designed to detect cancer cells and predict their response to cancer therapy by identifying specific methylation markers in patient DNA samples through PCR. "We look forward to enhancing our pharmacogenomic services with the BioTrove OpenArray system, which enables us to test our many proprietary methylation markers on clinical samples in a fast, high-throughput manner," says Wim Van Criekinge, vp, biomarker and pharmacogenomics research, OncoMethylome.

Under the terms of the multiyear agreement, BioTrove will supply OncoMethylome with OpenArray nanoplates and instrumentation for use in R&D of DNA methylation-based biomarkers.